CLAIMS

1. A compound of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

R^3 is hydrogen, halogen, C_1-C_4 alkyl, -CH_2OCH_3, methoxy, -C(O)OH, -$C(O)OCH_3$, C_3-C_5 cycloalkyl, 4-6 membered heterocycloalkyl, or benzyl, wherein the C_1-C_4 alkyl is optionally substituted by -OH or one, two, or three fluorine atoms, the methoxy is optionally substituted by one, two, or three fluorine atoms, and the C_3-C_5 cycloalkyl is optionally substituted by methyl or by one or two fluorine atoms;

R^4 is hydrogen or C_1-C_3 alkyl optionally substituted by -OH;

R^5 is hydrogen, halogen, cyano, C_1-C_3 alkyl, or -$C(O)NH_2$;

R^6 is hydrogen, halogen, C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), or -O-(C_3-C_5 cycloalkyl), wherein the -O-(C_1-C_4 alkyl) is optionally substituted by one, two, or three fluorine atoms;

R^7 is hydrogen, C_1-C_4 alkyl, or methoxy;

R^8 is -$(CHR^{11})_n$-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, or 9-10 membered heteroaryl,

wherein the -$(CHR^{11})_n$-4-8 membered heterocycloalkyl is optionally substituted by one, two, or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF_2, -CF_3, -CH_2CHF_2, -CH_2CF_3, methoxy, 4-6 membered heterocycloalkyl, and one or two fluorine atoms,

wherein the 5-8 membered heteroaryl is optionally substituted by oxo, cyano, methyl, -$[CH(R^{16})]_p[N(CH_3)_2]$, or a 6 membered heterocycloalkyl, which is optionally substituted by methyl, and

wherein the 9-10 membered heteroaryl is optionally substituted by methyl;

R^9 is hydrogen or fluoro;

R^{10} is hydrogen or C_{1-3} alkyl;

R^{11} is hydrogen or methyl;

R^{16} is hydrogen or methyl;

n is 0 or 1; and

p is 0 or 1.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

R^3 is hydrogen, halogen, C_1-C_4 alkyl, -CH_2OCH_3, methoxy, -C(O)OH, -$C(O)OCH_3$, C_3-C_5 cycloalkyl, 4-6 membered heterocycloalkyl, or benzyl, wherein the C_1-C_4 alkyl is optionally substituted by -OH or one, two, or three fluorine atoms, the methoxy is optionally substituted by one, two, or three fluorine atoms, and the C_3-C_5 cycloalkyl is optionally substituted by methyl or by one or two fluorine atoms;

R^4 is hydrogen or C_1-C_3 alkyl optionally substituted by -OH;

R^5 is hydrogen, halogen, cyano, C_1-C_3 alkyl, or -$C(O)NH_2$;

R^6 is hydrogen, halogen, C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), or -O-(C_3-C_5 cycloalkyl), wherein the -O-(C_1-C_4 alkyl) is optionally substituted by one, two, or three fluorine atoms;

R^7 is hydrogen, C_1-C_4 alkyl, or methoxy;

R^8 is -$(CHR^{11})_n$-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, or 9-10 membered heteroaryl,

wherein the -$(CHR^{11})_n$-4-8 membered heterocycloalkyl is optionally substituted by one, two, or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF_2, -CF_3, -CH_2CHF_2, -CH_2CF_3, methoxy, 4-6 membered heterocycloalkyl, and one or two fluorine atoms,

wherein the 5-8 membered heteroaryl is optionally substituted by oxo, cyano, methyl, -$[CH(R^{16})]_p[N(CH_3)_2]$, or a 6 membered heterocycloalkyl, which is optionally substituted by methyl, and

wherein the 9-10 membered heteroaryl is optionally substituted by methyl;

R^{10} is hydrogen or C_1-C_3 alkyl;

R^{11} is hydrogen or methyl;

R^{16} is hydrogen or methyl;

n is 0 or 1; and

p is 0 or 1.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having Formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

R^3 is hydrogen, halogen, C_1-C_4 alkyl, -CH_2OCH_3, methoxy, -C(O)OH, -$C(O)OCH_3$, C_3-C_5 cycloalkyl, 4-6 membered heterocycloalkyl, or benzyl, wherein the C_1-C_4 alkyl is optionally substituted by -OH or one, two, or three fluorine atoms, the methoxy is optionally substituted by one, two, or three fluorine atoms, and the C_3-C_5 cycloalkyl is optionally substituted by methyl or by one or two fluorine atoms;

R^4 is hydrogen or C_1-C_3 alkyl optionally substituted by -OH;

R^5 is hydrogen, halogen, cyano, C_1-C_3 alkyl, or -$C(O)NH_2$;

R^6 is hydrogen, halogen, C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), or -O-(C_3-C_5 cycloalkyl), wherein the -O-(C_1-C_4 alkyl) is optionally substituted by one, two, or three fluorine atoms;

R^7 is hydrogen, C_1-C_4 alkyl, or methoxy;

R^8 is -$(CHR^{11})_n$-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, or 9-10 membered heteroaryl,

wherein the -$(CHR^{11})_n$-4-8 membered heterocycloalkyl is optionally substituted by one, two, or three substituents independently selected from oxo, one or two methyl substituents, ethyl, -CHF_2, -CF_3, -CH_2CHF_2, -CH_2CF_3, methoxy, 4-6 membered heterocycloalkyl, and one or two fluorine atoms,

wherein the 5-8 membered heteroaryl is optionally substituted by oxo, cyano, methyl, -$[CH(R^{16})]_p[N(CH_3)_2]$, or a 6 membered heterocycloalkyl, which is optionally substituted by methyl, and

wherein the 9-10 membered heteroaryl is optionally substituted by methyl;

R^{10} is hydrogen or C_1-C_3 alkyl;

R^{11} is hydrogen or methyl;

R^{16} is hydrogen or methyl;

n is 0 or 1; and

p is 0 or 1.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen, chloro, C_1-C_4 alkyl, -CHF_2, -CF_3, -CF_2CH_3, -CH_2-CF_3, -CH_2OCH_3, methoxy, -O-CHF_2, -C(O)OH, -$C(O)OCH_3$, bicyclo[1.1.1]pentan-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or benzyl,

wherein the C_1-C_4 alkyl is optionally substituted by -OH, and

wherein the cyclopropyl is optionally substituted by methyl or two fluorine atoms.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^3 is cyclopropyl, R^4 is hydrogen and R^5 is hydrogen.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R^6 is methoxy and R^7 is methoxy.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^8 is azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, dioxanyl, morpholinyl, -$CH(CH_3)$-azetidinyl, -CH_2-pyrrolidinyl, -$CH(CH_3)$-morpholinyl, azaspiro[3.4]octanyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]oxazinyl, hexahydropyrido[3,4-d]pyrimidinyl

wherein the azetidinyl is optionally substituted by methoxy, fluoro or tetrahydrofuran,

wherein the pyrrolidinyl is optionally substituted by one substituent selected from oxo, methyl, ethyl, -CH_2CHF_2, methoxy, tetrahydrofuran and fluoro, or two, or three substituents independently selected from oxo, methyl and fluoro,

wherein the dioxanyl is optionally substituted by two methyl substituents,

wherein the piperidinyl is optionally substituted by one substituent selected from methyl, ethyl, -CH_2CHF_2, -CH_2CF_3, oxetanyl, and tetrahydrofuran, or two, or three substituents selected from methyl, and one or two fluorine atoms,

wherein the piperazine is optionally substituted by methyl or two substituents selected from oxo and methyl,

wherein the morpholinyl is optionally substituted by methyl or ethyl,

wherein the -CH_2-azetidinyl is optionally substituted by methyl or one or two fluorine atoms,

wherein the -$CH(CH_3)$-azetidinyl is optionally substituted by one fluorine atom,

wherein the -CH_2-pyrrolidinyl is optionally substituted by -CHF_2, -CF_3, two methyl substituents, or one or two fluorine atoms,

wherein the -CH_2-piperidinyl is optionally substituted by methyl, methoxy, or one or two fluorine atoms,

wherein the pyrazolyl is optionally substituted by methyl,

wherein the triazolyl is optionally substituted by methyl,

wherein the imidazolyl is optionally substituted by methyl,

wherein the pyridinyl is optionally substituted by one or two substituents selected from methyl and oxo,

wherein the pyrazinyl is optionally substituted by methyl or -$N(CH_3)_2$,

wherein the pyrimidinyl is optionally substituted by methyl, cyano, -$CH_2[N(CH_3)_2]$, -$N(CH_3)_2$, -$CH(CH_3)[N(CH_3)_2]$, or methyl-substituted piperazinyl,

wherein the pyridazinyl is optionally substituted by oxo or methyl, and

wherein the hexahydropyrido[3,4-d]pyrimidinyl is optionally substituted by methyl.

8. A compound selected from the group consisting of



,



,



,



,



,



5 ,



,



,



,



,



,



,


or1

,



,


abs

,



,


abs

,



,



,



,



,



, and



,

or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

9. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

10. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

11. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

12. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

13. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

14. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.

15. The compound of claim 8, or the tautomer thereof, or the pharmaceutically acceptable salt of the compound or the tautomer thereof, wherein the compound is:



or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or the tautomer thereof.